Kerry L. Reynolds

Oncology

75 Francis St
Boston, MA 02115

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 189 publications

Enfortumab Vedotin-Induced Cutaneous Toxic Effects and Survival in Urothelial Carcinoma.

Enfortumab Vedotin-Induced Cutaneous Toxic Effects and Survival in Urothelial Carcinoma.

Journal: JAMA dermatology

Published: July 29, 2026

Enfortumab vedotin-induced cutaneous toxicities and their association with survival in urothelial carcinoma.

Enfortumab vedotin-induced cutaneous toxicities and their association with survival in urothelial carcinoma.

Journal: medRxiv : the preprint server for health sciences

Published: June 04, 2026

Systemic Glucocorticoid Immunosuppression and Survival Among Immune Checkpoint Inhibitor Recipients.

Systemic Glucocorticoid Immunosuppression and Survival Among Immune Checkpoint Inhibitor Recipients.

Journal: JAMA network open

Published: May 22, 2026

Evaluating the safety of Janus kinase inhibitors in the management of severe immune-related adverse events.

Evaluating the safety of Janus kinase inhibitors in the management of severe immune-related adverse events.

Journal: Journal for immunotherapy of cancer

Published: May 16, 2026

A Novel Approach to Targeting DLL3 with Tarlatamab in a Patient with Medullary Thyroid Carcinoma after Progression on Selpercatinib.

A Novel Approach to Targeting DLL3 with Tarlatamab in a Patient with Medullary Thyroid Carcinoma after Progression on Selpercatinib.

Journal: Thyroid : official journal of the American Thyroid Association

Published: May 12, 2026

Refractory immune-related adverse events (irAEs) associated with immune checkpoint inhibitor therapy: a multiorgan management review.

Refractory immune-related adverse events (irAEs) associated with immune checkpoint inhibitor therapy: a multiorgan management review.

Journal: Expert opinion on drug safety

Published: April 17, 2026

Immune Checkpoint Inhibitors, Atherosclerotic Cardiovascular Events, and Plaque Progression Among Women With Cancer.

Immune Checkpoint Inhibitors, Atherosclerotic Cardiovascular Events, and Plaque Progression Among Women With Cancer.

Journal: Journal of the American Heart Association

Published: November 26, 2025

Pre-existing psoriasis and immune-related adverse events following immunotherapy for lung cancer.

Pre-existing psoriasis and immune-related adverse events following immunotherapy for lung cancer.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV

Published: November 17, 2025

Effect of Liver Metastases on Survival in Microsatellite-Stable Metastatic Colorectal Cancer Treated with Immune Checkpoint Inhibitors.

Effect of Liver Metastases on Survival in Microsatellite-Stable Metastatic Colorectal Cancer Treated with Immune Checkpoint Inhibitors.

Journal: Cancer research communications

Published: November 07, 2025

Utilization of Steroid Sparing Agents for Immune-Related Adverse Events (irAEs): Management Strategies and Considerations.

Utilization of Steroid Sparing Agents for Immune-Related Adverse Events (irAEs): Management Strategies and Considerations.

Journal: Current oncology reports

Published: October 28, 2025

Corrigendum to "Precision immunomodulation: Understanding and harnessing cytokine pathways to treat and prevent immune-related adverse events (irAEs)" [Best Pract Res Clin Haematol 38 2 2025].

Corrigendum to "Precision immunomodulation: Understanding and harnessing cytokine pathways to treat and prevent immune-related adverse events (irAEs)" [Best Pract Res Clin Haematol 38 2 2025].

Journal: Best practice & research. Clinical haematology

Published: September 07, 2025

Immune thrombocytopenia in patients treated with immune checkpoint inhibitors.

Immune thrombocytopenia in patients treated with immune checkpoint inhibitors.

Journal: Blood

Published: September 05, 2025

Showing 1-12 of 189

Last Updated: 09/26/2026